AAPL 250.9362 1.1636% MSFT 439.85 0.5624% NVDA 132.26 2.5987% GOOGL 190.36 1.0403% GOOG 191.585 0.7547% AMZN 224.7026 1.8967% META 605.1 1.3245% AVGO 221.57 -0.9167% TSLA 434.8 -1.211% TSM 195.3 -0.133% LLY 758.87 -0.7637% V 315.9 1.9756% JPM 234.325 1.7168% UNH 493.79 -1.1867% NVO 103.7 -2.1329% WMT 93.89 0.3634% LVMUY 130.52 0.7721% XOM 105.67 -0.7048% LVMHF 649.5 0.6649% MA 526.755 1.3068%
Last update at 2024-12-19T18:49:00Z
Verrica Pharmaceuticals Inc. (VRCA): Worst 52-Week Low Stock to Buy Now
Sun 29 Sep 24, 12:02 PM7 Short-Squeeze Stocks That Could Beat Down the Bears
Mon 15 Jul 24, 12:00 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -24.48700M | -35.08000M | -42.69400M | -28.20700M | -20.64800M |
| Minority interest | - | - | - | - | - |
| Net income | -27.67800M | -38.90300M | -45.49700M | -27.95000M | -20.64800M |
| Selling general administrative | 17.41M | 26.98M | 24.51M | 14.64M | 9.05M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 8.31M | 12.00M | - | - | 0.00000M |
| Reconciled depreciation | 0.72M | 0.47M | 0.23M | 0.26M | 0.02M |
| Ebit | -21.29600M | -30.90800M | -40.18100M | -30.33700M | -20.66800M |
| Ebitda | -20.87800M | -30.78500M | -39.66100M | -30.08000M | -20.64800M |
| Depreciation and amortization | 0.42M | 0.12M | 0.52M | 0.26M | 0.02M |
| Non operating income net other | -1.01900M | 0.12M | 0.52M | 1.87M | 1.23M |
| Operating income | -21.29600M | -30.90800M | -40.18100M | -30.08000M | -21.87800M |
| Other operating expenses | 30.33M | 42.91M | 40.18M | 30.08M | 21.88M |
| Interest expense | 2.17M | 4.29M | 3.03M | 0.00000M | 0.00000M |
| Tax provision | - | - | - | - | - |
| Interest income | 0.48M | 0.12M | 0.52M | 1.88M | 1.23M |
| Net interest income | -1.69600M | -4.17200M | -2.51200M | 1.88M | 1.23M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 3.19M | 3.82M | 2.80M | -0.25700M | 1.23M |
| Total revenue | 9.03M | 12.00M | 0.00000M | 0.00000M | 0.00000M |
| Total operating expenses | 29.60M | 42.91M | 40.18M | 30.08M | 21.88M |
| Cost of revenue | 0.72M | - | - | - | 0.00000M |
| Total other income expense net | -3.19100M | -4.17200M | -2.51300M | 1.87M | -0.00100M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -24.48700M | -35.08000M | -42.69400M | -28.20700M | -20.64800M |
| Net income applicable to common shares | -24.48700M | -35.08000M | -42.69400M | -28.20700M | -20.64800M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 81.60M | 44.72M | 80.12M | 74.15M | 68.42M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 2.54M | 4.84M | 3.97M | 2.18M | 2.97M |
| Total liab | 61.83M | 4.69M | 47.52M | 41.17M | 3.41M |
| Total stockholder equity | 19.76M | 40.03M | 32.60M | 32.99M | 65.02M |
| Deferred long term liab | - | - | - | 0.10M | - |
| Other current liab | 13.86M | 2.65M | 3.27M | 3.11M | 2.04M |
| Common stock | 0.00400M | 0.00400M | 0.00300M | 0.00300M | 0.00300M |
| Capital stock | 0.00400M | 0.00400M | 0.00300M | 0.00300M | 0.00300M |
| Retained earnings | -230.44800M | -163.45300M | -138.96600M | -103.88600M | -61.19200M |
| Other liab | - | - | - | 5.85M | - |
| Good will | - | - | - | - | - |
| Other assets | 0.00000M | 0.28M | 0.29M | 1.57M | 1.24M |
| Cash | 69.55M | 34.27M | 15.75M | 10.69M | 9.24M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 17.02M | 3.46M | 46.05M | 39.48M | 3.35M |
| Current deferred revenue | - | - | - | 0.50M | - |
| Net debt | -24.03700M | -32.74700M | 27.66M | 24.63M | -9.05300M |
| Short term debt | 0.70M | 0.30M | 41.94M | 35.51M | 0.13M |
| Short long term debt | - | - | 41.69M | 35.31M | - |
| Short long term debt total | 45.51M | 1.53M | 43.41M | 35.31M | 0.19M |
| Other stockholder equity | 250.21M | 203.48M | 171.60M | 136.87M | 126.18M |
| Property plant equipment | - | 3.89M | 3.89M | 4.94M | 2.20M |
| Total current assets | 77.53M | 39.12M | 74.33M | 65.47M | 64.98M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 40.03M | 32.60M | 32.99M | 65.02M |
| Short term investments | - | 0.00000M | 54.60M | 54.78M | 52.78M |
| Net receivables | 4.42M | 0.49M | - | - | - |
| Long term debt | 42.87M | - | - | 35.31M | - |
| Inventory | 1.02M | -0.48700M | - | - | - |
| Accounts payable | 2.46M | 0.51M | 0.84M | 0.35M | 1.19M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.00000M | - | -0.02900M | 0.00100M | 0.02M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.00400M | 0.00300M | 0.00300M | 0.00300M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -163.45300M | -138.96600M | -103.88600M | -61.19200M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.45M | 0.28M | 0.29M | 3.75M | 1.24M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 4.07M | 5.61M | 5.80M | 8.68M | 3.44M |
| Capital lease obligations | 2.64M | 1.53M | 1.72M | 1.89M | 0.19M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 54.52M | 0.09M | -1.88900M | 27.86M | -79.12000M |
| Change to liabilities | -0.59300M | 0.20M | -0.33800M | 0.01M | 1.86M |
| Total cashflows from investing activities | 54.04M | -0.99800M | -3.58000M | 25.95M | -79.89400M |
| Net borrowings | -43.76700M | 4.97M | 34.46M | 34.46M | 34.46M |
| Total cash from financing activities | -16.87000M | 33.65M | 35.23M | 0.42M | 99.38M |
| Change to operating activities | -0.97500M | -0.53200M | 1.97M | -1.95300M | 0.14M |
| Net income | -24.48700M | -35.08000M | -42.69400M | -28.20700M | -20.64800M |
| Change in cash | 18.52M | 5.07M | 1.45M | -1.03000M | 1.61M |
| Begin period cash flow | 15.75M | 10.69M | 9.24M | 10.27M | 8.66M |
| End period cash flow | 34.27M | 15.75M | 10.69M | 9.24M | 10.27M |
| Total cash from operating activities | -18.65000M | -27.58200M | -30.20700M | -27.40800M | -17.87400M |
| Issuance of capital stock | 26.90M | 28.12M | - | 0.00000M | 107.25M |
| Depreciation | 0.72M | 0.47M | 0.23M | 0.26M | 0.02M |
| Other cashflows from investing activities | -0.18000M | -0.20100M | -0.22100M | -1.22400M | -0.49900M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | -0.48700M | -0.48700M | 0.41M | -0.48700M | - |
| Sale purchase of stock | 26.90M | 28.68M | 0.45M | 0.42M | 78.38M |
| Other cashflows from financing activities | -0.01700M | 5.53M | 35.23M | 0.42M | 13.13M |
| Change to netincome | 6.80M | 7.50M | 10.62M | 3.33M | 2.25M |
| Capital expenditures | 0.30M | 0.88M | 1.47M | 0.68M | 0.77M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | -0.93700M | -0.51200M | 1.71M | -1.54700M | -0.92300M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | 18.52M | 5.07M | 1.45M | -1.03000M | 1.61M |
| Change in working capital | -1.80000M | -0.53500M | 1.64M | -1.72800M | 0.94M |
| Stock based compensation | 4.99M | 6.05M | 9.82M | 3.33M | 2.25M |
| Other non cash items | 1.93M | 1.44M | 0.94M | -1.06300M | -0.43500M |
| Free cash flow | -18.95200M | -28.46500M | -31.67700M | -28.09000M | -18.64800M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| VRCA Verrica Pharmaceuticals Inc |
-0.0221 3.44% | 0.62 | - | - | 56.87 | 14.83 | 52.51 | -4.3262 |
| NVO Novo Nordisk A/S |
-2.26 2.13% | 103.70 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.68 1.57% | 105.12 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-55.6951 12.45% | 391.80 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-4.445 0.62% | 710.17 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
44 West Gay Street, West Chester, PA, United States, 19380
| Name | Title | Year Born |
|---|---|---|
| Mr. Ted White | Pres, CEO & Director | 1965 |
| Mr. Joe Bonaccorso | Chief Commercial Officer | 1964 |
| Dr. Gary Goldenberg M.D. | Chief Medical Officer | 1977 |
| Mr. P. Terence Kohler | Chief Financial Officer | NA |
| Mr. Christopher G. Hayes | Chief Legal Officer, Sec., Chief Compliance Officer & Gen. Counsel | 1964 |
| Mr. Eugene Scavola | Exec. VP of Technical Operations | NA |
| Dr. Bradley J. Catalone MBA, Ph.D. | Head of Drug Devel. | NA |
| Mr. Ted White | President, CEO & Director | 1965 |
| Mr. Christopher G. Hayes | Chief Legal Officer, Secretary, Chief Compliance Officer & General Counsel | 1964 |
| Mr. Eugene Scavola | Executive Vice President of Technical Operations | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...